Secular Growth

438 tickers in this investment thesis
Ranks this page's recent reports by score.
Alkermes plc
ALKS·Healthcare
C ★★Sell
Current$45.34
Oct 31, 2026

Alkermes offers meaningful neuroscience growth potential through LUMRYZ and alixorexton, but acquisition-related earnings pressure, clinical uncertainty, and demanding cash-flow valuation constrain near-term investment appeal.

Score
63
Calix, Inc.
CALX·Technology
B ★★★Hold
Current$36.82
Target$46.00
Return+24.9%
Oct 31, 2026

Calix can compound value through broadband platform adoption, expanding managed services, and improving operating leverage, but hardware dependence, component inflation, and shareholder dilution limit the certainty of sustained earnings growth.

Score
71
Teradyne, Inc.
TER·Technology
A ★★★★Buy
Current$276.01
Target$330.00
Return+19.6%
Oct 30, 2026

Teradyne combines a durable semiconductor testing moat with growing AI-driven demand and strong cash generation, although cyclical equipment spending and demanding growth expectations could produce substantial earnings volatility.

Score
78
Ventas, Inc.
VTR·Real Estate
B ★★★Hold
Current$85.03
Target$93.50
Return+10.0%
Oct 30, 2026

Ventas benefits from strong senior housing demand, improving occupancy, and acquisition-driven growth, but elevated FFO valuation and substantial equity dilution limit the margin of safety for new investors.

Score
70
Baker Hughes Company
BKR·Energy
B ★★★Hold
Current$54.99
Target$58.90
Return+7.1%
Oct 30, 2026

Baker Hughes combines a durable energy equipment franchise with expanding industrial growth and aftermarket opportunities, but elevated acquisition debt and a premium historical valuation limit near-term upside.

Score
71
Robinhood Markets, Inc.
HOOD·Financials
B ★★★Hold
Current$82.66
Target$96.00
Return+16.1%
Oct 30, 2026

Robinhood is building a scalable digital financial ecosystem through trading, subscriptions, and new financial products, but elevated growth expectations, trading cyclicality, and regulatory uncertainty constrain its risk-adjusted upside.

Score
66
CenterPoint Energy, Inc.
CNP·Utilities
C ★★Sell
Current$42.21
Oct 30, 2026

CenterPoint Energy benefits from durable regulated utility demand and accelerating Houston-area infrastructure investment, but high leverage, persistent negative free cash flow, dilution risk, and a demanding valuation constrain shareholder upside.

Score
55
CECO Environmental Corp.
CECO·Industrials
B ★★★Hold
Current$54.70
Target$63.20
Return+15.5%
Oct 30, 2026

CECO Environmental's record backlog and Thermon integration offer substantial industrial growth and earnings upside, but acquisition debt, dilution, and weak reported cash conversion remain important obstacles to durable shareholder returns.

Score
66
Curbline Properties Corp.
CURB·Real Estate
B ★★★Hold
Current$28.73
Target$31.46
Return+9.5%
Oct 30, 2026

Curbline offers a differentiated convenience-retail REIT platform with attractive leasing growth and acquisition opportunities, but premium valuation, equity dilution, and financing costs constrain near-term shareholder returns.

Score
65
Kiniksa Pharmaceuticals International, plc
KNSA·Healthcare
B ★★★Hold
Current$97.56
Target$101.22
Return+3.8%
Oct 30, 2026

Kiniksa offers rapid ARCALYST growth, improving cash generation, and a promising IL-1 pipeline, but single-product dependence, continued dilution, and a demanding valuation constrain its near-term risk-reward.

Score
72